Journal of Clinical Oncology, Vol 10, 228-236, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma

U Tirelli, V Zagonel, D Errante, D Serraino, R Talamini, M De Cicco, A Carbone and S Monfardini
Division of Medical Oncology, Centro di Riferimento Oncologico, INRCCS, Aviano, Italy.

PURPOSE: A prospective trial with a new combination of etoposide, mitoxantrone, and prednimustine (VMP), specifically devised for elderly patients with non-Hodgkin's lymphoma (NHL), was undertaken. PATIENTS AND METHODS: Between January 1987 and April 1990, 52 consecutive unselected patients older than 70 years (median age, 75.6 years) with stage I to IV intermediate- and high-grade NHL, or with stage III to IV low-grade malignancy with symptomatic disease received etoposide and prednimustine 80 mg/m2 orally for 5 days and mitoxantrone 8 to 10 mg/m2 day 1 intravenously (IV), every 21 days. Fourteen patients were previously treated. RESULTS: Among the 48 assessable patients, the objective response rate was 81%; 46% of the patients achieved a complete response (CR). The overall toxicity seemed to be acceptable, with 15 (7%) episodes of grade 4 leukopenia and 41 (18%) episodes of grade 3, over a total of 226 administered cycles. The median survival was 12 months. The patients who obtained CR have a longer survival than those who did not (34 v 8 months; P less than .001). Fifty-eight percent of patients achieving CR were free from relapse at 24 months; up to 36 months from the start of therapy, 25% were free from relapse. As far as patients affected by diffuse histiocytic lymphoma, 66% of previously untreated patients obtained a CR, and 55% of them were still disease-free at 24 months from the start of therapy. CONCLUSION: We conclude that VMP is effective, well tolerated, and feasible on an outpatient basis in an unselected, elderly population affected by unfavorable NHL.

This article has been cited by other articles:

				J.K. Doorduijn, B. van der Holt, G.W. van Imhoff, K.G. van der Hem, M.H.H. Kramer, M.H.J. van Oers, G.J. Ossenkoppele, M.R. Schaafsma, L.F. Verdonck, G.E.G. Verhoef, et al. CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., August 15, 2003; 21(16): 3041 - 3050. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, F. Gherlinzoni, S. Storti, A. Zaccaria, E. Pavone, L. Moretti, P. Gentilini, L. Guardigni, A. De Renzo, P. P. Fattori, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients Ann. Onc., September 1, 2002; 13(9): 1364 - 1369. [Abstract] [Full Text] [PDF]

				P. N. Mainwaring, D. Cunningham, W. Gregory, P. Hoskin, B. Hancock, A. J. Norton, K. MacLennan, P. Smith, G. V. Hudson, and D. Linch Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO Blood, May 15, 2001; 97(10): 2991 - 2997. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, S. Storti, A. Zaccaria, L. Moretti, M. Magagnoli, E. Pavone, P. Gentilini, L. Guardigni, M. Gobbi, P. P. Fattori, et al. Elderly Aggressive-Histology Non-Hodgkin's Lymphoma: First-Line VNCOP-B Regimen Experience on 350 Patients Blood, July 1, 1999; 94(1): 33 - 38. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, E. Pavone, S. Storti, L. Moretti, P. P. Fattori, L. Guardigni, B. Falini, M. Gobbi, P. Gentilini, V. M. Lauta, et al. Randomized Trial With or Without Granulocyte Colony-Stimulating Factor as Adjunct to Induction VNCOP-B Treatment of Elderly High-Grade Non-Hodgkin's Lymphoma Blood, June 1, 1997; 89(11): 3974 - 3979. [Abstract] [Full Text] [PDF]

				J. O. Armitage Treatment of Non-Hodgkin's Lymphoma N. Engl. J. Med., April 8, 1993; 328(14): 1023 - 1030. [Full Text]